Evecxia Therapeutics is a clinical-stage company dedicated to realizing the therapeutic potential of amplifying serotonin synthesis to treat disorders of the brain. Evecxia has two drug candidates in clinical development. EVX-101, an oral pill being developed as an adjunctive treatment for depression in patients where first-line antidepressants alone are inadequate, and EVX-301, an intravenous drug, in development as rescue therapy for depression patients experiencing suicidal ideation. The company has a comprehensive portfolio of issued and pending patents on the 5-HTP slow-release/serotonin amplification method, formulations, and related technologies.